| |

Wonderland Miami 2023: New Psychedelic Marvels, Practical Business Updates

Wonderland 2023: New Psychedelic Marvels, Practical Business Updates
(l. to r.) Marik Hazan, Jeffrey Martin, Dillan DiNardo, Richard Titus, Toby Pasman | Photo Credit: Dave Hodes

The wonders of psychedelics—the what-ifs, the how-tos, the why-nots—were on hand on three main stages at Miami’s Ice Palace Film Studios at the 2023 Wonderland Conference, November 9-11, featuring over 250 speakers, 60 exhibitors, and approximately 5,000 attendees.

The conference this year focused more on the fascinating applications of psychedelics either planned or in the works, rather than looking at the markers of a maturing industry, which was the theme of the 2022 Wonderland conference presentations.

This third Wonderland represented an energetic deep dive into how psychedelics function to benefit human health and wellness; the role of AI in the study of psychedelics; and how psychedelics help create a positive body/soul consciousness that can be part of personal transformation.

Extending life through psychedelics, and what that could mean for the future of humanity, was the subject of many discussions during the conference. There were 24 sessions about longevity spread out over a total of 134 Wonderland sessions.

But if there was a theme for the conference, it was the amazing tech-derived discoveries about psychedelics.
Psychedelics may be able to heal hate, as explained by Rabbi Harry Rozenberg, co-founder of Trippy VC, in one of the more audience-hushing presentations.

Rabbi Harry Rozenberg, co-founder of Trippy VC
Rabbi Harry Rozenberg, co-founder of Trippy VC | Photo Credit: Dave Hodes

In another fascinating presentation, Scotch McClure, CEO and chairman of Maxwell Biosciences, talked about how microbes are psychedelics working within the microbiome, and that 95% of a body’s serotonin comes from the microbiome. “It can change the way someone views the outside world,” he said.

Wonderland Miami psychedelic conference 2023
Scotch McClure, CEO and chairman of Maxwell Biosciences | Photo Credit: Dave Hodes

He also talked about wellness research that could rid the body of viruses, and enable humans to live well beyond 125 years.

“The human body is really about designed obsolescence,” McClure said. “If you can wash out the system good enough, then you should be able to extend the lifespan. So let’s wash it and put it in the dishwasher and see if we can get some of the pathogens out and continue to use it.”

Dillan DiNardo, CEO of Mindstate Design Labs, explained how his work in building a large language database from reports by psychonauts about their personal trip experiences is being used in an AI model to help quantify the psychedelic experience, and dissect all the components of the biology of consciousness.

Wonderland 2023: New Psychedelic Marvels, Practical Business Updates
(l. to r.) Marik Hazan, Jeffrey Martin, Dillan DiNardo, Richard Titus, Toby Pasman | Photo Credit: Dave Hodes

His company is designing new psychedelic drugs using that technology. “So if you look at how DMT interacts with the brain, it’s very different from how LSD interacts with the brain, and that’s very different from how ibogaine interacts with the brain,” he said. “So what all of these technologies allow us to do is draw a chain from subjective experience to the drug to the pharmacology of the drug to the receptor.”

There were practical business operations sessions as well during Wonderland. 

Psychedelics has returned to its economic boom positioning after a short crash, in part because of the coming rollout out of FDA-approved MDMA treatment for PTSD, according to a psychedelic investment session. 

Sisi Lee, the senior data architect for Porta Sophia, talked about the difficulty of finding evidence of prior art for psychedelics patents, and how companies are getting caught up in overly broad patenting schemes without doing the required due diligence.

Wonderland Conference Miami 2023
Sisi Lee, the senior data architect for Porta Sophia | Photo Credit: Dave Hodes

But a key observation about longevity came from Bryan Johnson, CEO of Kernel and wearing a shirt that read “Don’t Die,” who said that he now ages slower than 97 percent of 36 year-olds using a nutrition program his company developed.

Wonderland Miami 2023
Bryan Johnson, CEO of Kernel | Photo Credit: Dave Hodes

“To me, psychedelics are substances that can help us bridge outside of the constraints of our mind,” he said.

 

Similar Posts

  • Top 5 Catalysts for Psychedelic Stocks In The Second Half of 2021 (MNMD,CMPS,ATAI,TRYP, CYBN & MORE)

    What are top 5 catalysts for psychedelic stocks in the second half of 2021? Stay tuned to hear how stocks like MindMed (NASDAQ: MNMD),
    (NEO:MMED), Compass Pathways (NASDAQ: CMPS), atai Life Sciences ( NASDAQ: ATAI), Tryp Therapeutics, Cybin and more will affect the psychedelic industry in 2021.

    Timestamps:

    0:00 – Intro
    1:38 – #5: A New Psychedelics ETF (PSIL)
    4:57 – #4:California Decriminalizing possession of psychedelics, and Legalising the personal production of Psilocybin
    7:30 – #3:The commencement of MANY phase 2a trials
    10:16 – #2: MindMed’s Project Lucy phase 2b trial begins
    11:47 – #1: Compass Pathways phase 2b trial results released

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Check out our website: thepsychedelicinvestor.com

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    #MindMed #MNMD #PsychedelicStocks

  • BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]

    Hello Psychedelic Investors! Today, we will focus on MindMed’s 2021 Investors Deck and Project Lucy & Project Layla’s clinical trials updates.
    MindMed, ticker symbol MMED on the Canadian NEO Stock exchange, and MMEDF on the American OTC Market has updated their 2021 Investors Deck (TWICE) in this year. As a fellow MindMed geek, I did my due diligence to compare the information on both decks and there’s a few clinical trial changes and a few other updates I found important to discuss.

    In this episode, we will discuss:

    Timecodes
    0:00 – Intro
    3:02 – MindMed’s Project Lucy Updates
    6:27 – MMED’s18-MC And Microdosing Updates
    9:00 – LSD to treat Suicide Headaches
    11:04 – Phase 1 Updates
    14:06 – Stats Updates
    15:32 – MindMed Stock Speculation Zone

    Important to mention that after we shot this video, MindMed did answer our inquiry about the removed readout with “Hello – Sorry for the delay. We plan on filing the IND for Project Lucy in Q3 of 2021.”
    I’m not sure if that means that there will be a readout in Q3 as well…

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video by Pressmaster from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock

  • Digital Therapeutics and Psychedelic Medicines || MindMed ‘s SECRET WEAPON?!?

    Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.

    Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.

    Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.

    1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
    2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    If you wish to collaborate, send us an email at:
    thepsychedelicinvestor@gmail.com

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Music: www.bensound.com

    Time Stamps:

    0:00 – Intro
    10:08 – Implications for MindMed and Atai

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #MMEDNews

  • Government: Mind Control

    Explore the intriguing and controversial topic of government mind control in this thought-provoking article.